After hours today (March 2), the science and innovation board Hangzhou Mdk Opto Electronic Corporation Limited(688079) , Chengdu M&S Electronics Technology Co.Ltd(688311) announced its first repurchase plan since listing.
In addition to the two companies, a number of science and Innovation Board companies have recently disclosed their first repurchase plan / plan. According to the statistics of the science and Innovation Board daily, since January 2022, seven companies have joined the repurchase team (see the figure below). In the same period last year, only two companies of Kechuang board announced the repurchase plan.
All the above companies said that the repurchased shares intend to implement the employee stock ownership plan or equity incentive at an appropriate time in the future.
except Touchstone International Medical Science Co.Ltd(688013) , the latest prices of other stocks are below the repurchase price. Pharmaceutical companies have a larger discount and a higher total repurchase capital cap. The 2-day closing prices of Cansino Biologics Inc(688185) , Qingdao Haier Biomedical Co.Ltd(688139) and Qingdao Haier Biomedical Co.Ltd(688139) are 45% and 29% lower than the repurchase capital cap respectively. The repurchase capital cap of Cansino Biologics Inc(688185) ranks first among the seven companies
Looking into the entire A-share market, since the beginning of this year, 15 pharmaceutical companies have issued repurchase plans, which not only ranks first in the number of industries, but also the overall scale of the upper limit of repurchase funds in the pharmaceutical and biological industry far exceeds that in other industries, reaching 2.38 billion yuan , and the leading medical device Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) has thrown out a repurchase plan of up to 1 billion yuan.
At present, the repurchase plans of Qingdao Haier Biomedical Co.Ltd(688139) and Cansino Biologics Inc(688185) have made progress: as of February 28, 2022, Qingdao Haier Biomedical Co.Ltd(688139) has paid 49.85 million yuan to repurchase 680000 shares, accounting for 0.21% of the total share capital of the company. The highest and lowest transaction prices are 74.48 yuan / share and 71.72 yuan / share respectively Cansino Biologics Inc(688185) accumulatively paid 84.82 million yuan to buy back 25000 shares, accounting for 0.13% of the total share capital of the company. The highest and lowest transaction prices were 269.07 yuan / share and 253.02 yuan / share respectively.
except for pharmaceutical companies, the total market value of other companies that announced repurchase was less than 7 billion yuan, and their fundamentals had bright spots
▍ Beijing Bayi Space Lcd Technology Co.Ltd(688181) is the only hybrid liquid crystal material enterprise listed separately. At present, it is deepening strategic cooperation with BOE to provide mixed crystal materials for LCD, and the product supply of its 10.5 generation lines in Hefei and Wuhan continues to grow. The company previously said that the decline in panel prosperity is mainly reflected in the decline in panel prices, which has little impact on shipments, so it has little impact on the use of liquid crystal materials. At the same time, panel manufacturers are more willing to use domestic materials to further reduce costs under difficult circumstances, and the periodicity of the company’s products is not obvious.
Sinolink Securities Co.Ltd(600109) analyst Chen Yi said that the transfer of panel industry chain and the improvement of mixed crystal localization rate will drive Beijing Bayi Space Lcd Technology Co.Ltd(688181) performance up.
▍ Jiangsu Feymer Technology Co.Ltd(688350) with hydrophilic functional polymer materials as the core, it serves water-based industrial fields such as water ecological protection and industrial greening. The company has admitted that the low growth rate of revenue and net profit in recent years is mainly limited by the production capacity. The company’s production capacity has not increased since 2015. Membrane materials and equipment account for a small proportion of the company’s overall revenue and are also new entrants in the industry. However, the performance test data of pilot products have exceeded the imported products. After the initial fund-raising project is put into operation, the product will achieve mass production.
Jiangsu Feymer Technology Co.Ltd(688350) previously said that its annual output of 33000 tons of special chemicals for water treatment and industrial water process and its supporting 16000 tons of monomer expansion project and 950 sets / year separation membrane equipment manufacturing project are expected to be officially put into operation in the second quarter of 2022.
▍ Hangzhou Mdk Opto Electronic Corporation Limited(688079) body fruit chain. Its products and services applied to Apple mobile phone industry chain are mainly precision processing services for sensor ceramic substrates and optical connectors for 3D structured light modules. The company has obvious transformation intention in recent years. Last year, it announced that it plans to invest 1 billion yuan to build a semiconductor device project with an annual output of 2 billion pieces / set, It plans to invest US $9.6 million (about 60 million yuan) to establish a holding subsidiary to develop products used in mobile phones, display equipment, high-end cars, AR / VR and other fields.
▍ Chengdu M&S Electronics Technology Co.Ltd(688311) main products include satellite navigation, satellite communication and other products. At present, it has entered the performance cashing period, and the company’s net profit in 2021 increased by 31% year-on-year. In a recent survey conducted by institutions, Chengdu M&S Electronics Technology Co.Ltd(688311) said that the R & D investment in the first three quarters of 2021 increased by 87.52% year-on-year, mainly due to the increase of R & D tasks. The growth of revenue during this period was mainly due to the increase of orders of the company’s satellite navigation series products compared with the previous year and the expansion of revenue scale during the reporting period.
